Skip to main content
Clinical Trials/IRCT20191022045196N2
IRCT20191022045196N2
Recruiting
Phase 2

Evaluating the effect of mirtazapine on anxiety in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Parkinson’s disease.
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
64
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Men and women over 17 years old
  • Patient with Parkinson's disease according to UKPDSBB criteria
  • Patient with mild/moderate Parkinson’s disease according to Hoehn and Yahr Scale (HY score \= 1\-3\)
  • Self\-report or clinical diagnosis of anxiety
  • Patients who have signed informed consent to participate in the study

Exclusion Criteria

  • Pregnant and lactating women
  • Parkinson's patients with onset of disease in less than 1 year
  • Unstable medication for Parkinson's disease during the last two weeks
  • Parkinson's patients with DBS
  • Patients with other neurodegenerative diseases like multiple system atrophy (MSA), Huntington's and etc.
  • Patients with major depressive disorder
  • A history of using SSRIs, SNRIs, benzodiazepines and ß\-blockers during the last 4 weeks
  • A history of using MAO inhibitors
  • A history of alcohol and substance abuse
  • A history of acute stress during the last 3 months

Outcomes

Primary Outcomes

Not specified

Similar Trials